BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Groot VP, van Santvoort HC, Rombouts SJ, Hagendoorn J, Borel Rinkes IH, van Vulpen M, Herman JM, Wolfgang CL, Besselink MG, Molenaar IQ. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB 2017;19:83-92. [DOI: 10.1016/j.hpb.2016.11.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 D'Haese JG, Renz BW, Ilmer M, Werner J. [Surgery for isolated local recurrence and metachronous oligometastasis in pancreatic cancer]. Chirurg 2020;91:628-35. [PMID: 32424598 DOI: 10.1007/s00104-020-01190-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Sato H, Yoshida R, Yasui K, Umeda Y, Yoshida K, Fuji T, Kumano K, Takagi K, Yagi T, Fujiwara T. Feasibility of local therapy for recurrent pancreatic cancer. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.05.004] [Reference Citation Analysis]
3 Halle-Smith JM, Hall L, Daamen LA, Hodson J, Pande R, Young A, Jamieson NB, Lamarca A, van Santvoort HC, Molenaar IQ, Valle JW, Roberts KJ. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2021;47:2248-55. [PMID: 34034941 DOI: 10.1016/j.ejso.2021.04.031] [Reference Citation Analysis]
4 Hu D, Ansari D, Zhou Q, Sasor A, Hilmersson KS, Bauden M, Jiang Y, Andersson R. Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma. BMC Cancer. 2018;18:1096. [PMID: 30419838 DOI: 10.1186/s12885-018-5013-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
5 Franck C, Hass P, Malfertheiner P, Ricke J, Seidensticker M, Venerito M. Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. Digestion 2018;98:69-74. [DOI: 10.1159/000487359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
6 Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther 2019;12:3387-400. [PMID: 31118690 DOI: 10.2147/OTT.S176700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
7 Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery 2018;267:936-45. [DOI: 10.1097/sla.0000000000002234] [Cited by in Crossref: 165] [Cited by in F6Publishing: 86] [Article Influence: 41.3] [Reference Citation Analysis]
8 Groot VP, Gemenetzis G, Blair AB, Ding D, Javed AA, Burkhart RA, Yu J, Borel Rinkes IH, Molenaar IQ, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Wolfgang CL, He J. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2018;25:2475-83. [PMID: 29948425 DOI: 10.1245/s10434-018-6558-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
9 Groot VP, Wolfgang CL, He J. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma? Ann Surg Oncol 2018;25:806-7. [DOI: 10.1245/s10434-018-6820-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
10 Gonzales BA, Diniz AL, Torres SM, Salvador de Castro Ribeiro H, Correia de Farias I, Luís de Godoy A, Coimbra FJF, Fonseca de Jesus VH. Patterns of disease relapse and posttreatment follow-up of patients with resected pancreatic adenocarcinoma: A single-center analysis. J Surg Oncol 2022. [PMID: 35699399 DOI: 10.1002/jso.26985] [Reference Citation Analysis]
11 Lai HC, Lee MS, Liu YT, Lin KT, Hung KC, Chen JY, Wu ZF. Propofol-based intravenous anesthesia is associated with better survival than desflurane anesthesia in pancreatic cancer surgery. PLoS One 2020;15:e0233598. [PMID: 32437450 DOI: 10.1371/journal.pone.0233598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Miyasaka Y, Ohtsuka T, Matsuda R, Mori Y, Nakata K, Ohuchida K, Nakamura M. High-risk lesions in the remnant pancreas: fate of the remnant pancreas after pancreatic resection for pancreatic cancer and intraductal papillary mucinous neoplasms. Surg Today 2020;50:832-40. [PMID: 31346809 DOI: 10.1007/s00595-019-01852-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Luu AM, Belyaev O, Höhn P, Praktiknjo M, Janot M, Uhl W, Braumann C. Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. J Gastrointest Oncol 2021;12:474-83. [PMID: 34012641 DOI: 10.21037/jgo-20-433] [Reference Citation Analysis]
14 Driescher C, Fuchs K, Haeberle L, Goering W, Frohn L, Opitz FV, Haeussinger D, Knoefel WT, Keitel V, Esposito I. Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer. Cancers (Basel) 2020;13:E39. [PMID: 33375555 DOI: 10.3390/cancers13010039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR, Jackson JF, Le DT, Jaffee EM, Zheng L, Laheru DA, He J, Pawlik TM, Weiss MJ, Wolfgang CL, Herman JM. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Ann Surg Oncol 2018;25:280-9. [PMID: 29063299 DOI: 10.1245/s10434-017-6134-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
16 Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes IHMB, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019;269:1154-1162. [PMID: 31082915 DOI: 10.1097/sla.0000000000002734] [Cited by in Crossref: 83] [Cited by in F6Publishing: 50] [Article Influence: 41.5] [Reference Citation Analysis]
17 Wang G, Pan J, Zhang L, Wang C. Overexpression of grainyhead-like transcription factor 2 is associated with poor prognosis in human pancreatic carcinoma. Oncol Lett 2019;17:1491-6. [PMID: 30675204 DOI: 10.3892/ol.2018.9741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Iacobuzio-Donahue CA, Michael C, Baez P, Kappagantula R, Hooper JE, Hollman TJ. Cancer biology as revealed by the research autopsy. Nat Rev Cancer 2019;19:686-97. [PMID: 31519982 DOI: 10.1038/s41568-019-0199-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
19 Daamen LA, Groot VP, Heerkens HD, Intven MP, van Santvoort HC, Molenaar IQ. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. HPB 2018;20:297-304. [DOI: 10.1016/j.hpb.2017.11.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
20 Safi SA, Haeberle L, Fluegen G, Lehwald-Tywuschik N, Krieg A, Keitel V, Luedde T, Esposito I, Rehders A, Knoefel WT. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Pancreatology 2021;21:787-95. [PMID: 33775563 DOI: 10.1016/j.pan.2021.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Choi M, Kim NW, Hwang HK, Lee WJ, Kang CM. Repeated Pancreatectomy for Isolated Local Recurrence in the Remnant Pancreas Following Radical Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Pooled Analysis. J Clin Med 2020;9:E3945. [PMID: 33291378 DOI: 10.3390/jcm9123945] [Reference Citation Analysis]
22 Okano N, Mizutani T, Nagashima F, Furuse J. Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer. Lancet Oncol 2021;22:e423. [PMID: 34592184 DOI: 10.1016/S1470-2045(21)00489-7] [Reference Citation Analysis]
23 Ge JC, Tao M, Li L, Ma ZL, Jiang B, Yuan CH, Wang HY, Peng Y, Xiu DR. Nomogram and competing risk model to predict recurrence after curative surgical resection of PDAC. Pancreatology 2021:S1424-3903(21)00149-6. [PMID: 34001437 DOI: 10.1016/j.pan.2021.04.010] [Reference Citation Analysis]
24 Omari J, Heinze C, Wilck A, Hass P, Seidensticker M, Seidensticker R, Mohnike K, Ricke J, Pech M, Powerski M. Efficacy and safety of CT-guided high-dose-rate interstitial brachytherapy in primary and secondary malignancies of the pancreas. Eur J Radiol 2019;112:22-7. [PMID: 30777214 DOI: 10.1016/j.ejrad.2018.12.020] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Mizumoto T, Terashima K, Matsuo Y, Nagano F, Demizu Y, Mima M, Sulaiman NS, Tokumaru S, Okimoto T, Toyama H, Fukumoto T. Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2019;26:2587-94. [PMID: 31147994 DOI: 10.1245/s10434-019-07471-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
26 Zhu X, Cao Y, Zhang H. Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer - Authors' reply. Lancet Oncol 2021;22:e424. [PMID: 34592185 DOI: 10.1016/S1470-2045(21)00529-5] [Reference Citation Analysis]
27 Groot VP, Daamen LA, Hagendoorn J, Borel Rinkes IH, Busch OR, van Santvoort HC, Besselink MG, Molenaar IQ. Current Strategies for Detection and Treatment of Recurrence of Pancreatic Ductal Adenocarcinoma After Resection: A Nationwide Survey. Pancreas 2017;46:e73-5. [DOI: 10.1097/mpa.0000000000000899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
28 Aravindan S, Somasundaram DB, Somasundaram ST, Natarajan M, Herman TS, Aravindan N. Targeting acquired oncogenic burden in resilient pancreatic cancer: a novel benefit from marine polyphenols. Mol Cell Biochem 2019;460:175-93. [PMID: 31367889 DOI: 10.1007/s11010-019-03579-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Hugenschmidt H, Labori KJ, Borgen E, Brunborg C, Schirmer CB, Seeberg LT, Naume B, Wiedswang G. Preoperative CTC-Detection by CellSearch® Is Associated with Early Distant Metastasis and Impaired Survival in Resected Pancreatic Cancer. Cancers (Basel) 2021;13:485. [PMID: 33513877 DOI: 10.3390/cancers13030485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Simmerman E, Chung J, Lawson A, Kruse E. Application of Irreversible Electroporation Ablation as Adjunctive Treatment for Margin Enhancement: Safety and Efficacy. Journal of Surgical Research 2020;246:260-8. [DOI: 10.1016/j.jss.2019.06.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Wu H, Guo JC, Yang SH, Tien YW, Kuo SH. Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer. J Clin Med 2019;8:E1115. [PMID: 31357636 DOI: 10.3390/jcm8081115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
32 Shen Y, Zhu X, Cao F, Xie H, Ju X, Cao Y, Qing S, Jia Z, Gu L, Fang F, Zhang H. Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases. Front Oncol 2021;11:729490. [PMID: 34796108 DOI: 10.3389/fonc.2021.729490] [Reference Citation Analysis]
33 Mihailidou C, Papakotoulas P, Papavassiliou AG, Karamouzis MV. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. Oncotarget 2018;9:10360-74. [PMID: 29535812 DOI: 10.18632/oncotarget.23164] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
34 Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G, Zhang H. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. The Lancet Oncology 2022;23:e105-15. [DOI: 10.1016/s1470-2045(22)00066-3] [Reference Citation Analysis]
35 Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G, Zhang H. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2021;22:1093-102. [PMID: 34237249 DOI: 10.1016/S1470-2045(21)00286-2] [Reference Citation Analysis]
36 Kang CM, Lee WJ. Is Laparoscopic Pancreaticoduodenectomy Feasible for Pancreatic Ductal Adenocarcinoma? Cancers (Basel) 2020;12:E3430. [PMID: 33218187 DOI: 10.3390/cancers12113430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
37 Groot VP, Daamen LA, Hagendoorn J, Borel Rinkes IHM, van Santvoort HC, Molenaar IQ. Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma. J Surg Res 2018;221:152-60. [PMID: 29229122 DOI: 10.1016/j.jss.2017.08.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
38 Heger U, Mack C, Tjaden C, Pan F, Pausch T, Hinz U, Sommer CM, Hackert T. Open irreversible electroporation for isolated local recurrence of pancreatic ductal adenocarcinoma after primary surgery. Pancreatology 2021;21:1349-55. [PMID: 34404600 DOI: 10.1016/j.pan.2021.08.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Sung MK, Park Y, Kwak BJ, Jun E, Lee W, Song KB, Lee JH, Hwang DW, Kim SC. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. Biomedicines 2021;9:1706. [PMID: 34829935 DOI: 10.3390/biomedicines9111706] [Reference Citation Analysis]
40 Daamen LA, Groot VP, Intven MPW, Besselink MG, Busch OR, Koerkamp BG, Mohammad NH, Hermans JJ, van Laarhoven HWM, Nuyttens JJ, Wilmink JW, van Santvoort HC, Molenaar IQ, Stommel MWJ; Dutch Pancreatic Cancer Group. Postoperative surveillance of pancreatic cancer patients. Eur J Surg Oncol 2019;45:1770-7. [PMID: 31204168 DOI: 10.1016/j.ejso.2019.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
41 Mathy RM, Fritz F, Mayer P, Klauss M, Grenacher L, Stiller W, Kauczor HU, Skornitzke S. Iodine concentration and tissue attenuation in dual-energy contrast-enhanced CT as a potential quantitative parameter in early detection of local pancreatic carcinoma recurrence after surgical resection. Eur J Radiol 2021;143:109944. [PMID: 34482176 DOI: 10.1016/j.ejrad.2021.109944] [Reference Citation Analysis]
42 Jun E, Kim SC, Lee CM, Oh J, Lee S, Shim IK. Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft. Sci Rep 2017;7:12381. [PMID: 28959053 DOI: 10.1038/s41598-017-12670-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
43 Choi M, Lee SJ, Shin DM, Hwang HK, Lee WJ, Kang CM. Laparoscopic repeated pancreatectomy for isolated local recurrence in remnant pancreas following laparoscopic radical pancreatectomy for pancreatic ductal adenocarcinoma: Two cases report. Ann Hepatobiliary Pancreat Surg 2020;24:542-6. [PMID: 33234761 DOI: 10.14701/ahbps.2020.24.4.542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]